- More than 474,000 people globally have leukemia, and acute leukemia is the most aggressive type.
- In a new clinical trial, of the 60 people with certain types of acute leukemia who took a new drug called revumenib, 30% experienced complete remission of the disease.
- Researchers are now hoping to carry out phase 2 trials and further studies to confirm these benefits.
As of 2020, more than 474,000 people around the world have leukemia — a cancer of the blood.
Of the two main types of leukemia, acute leukemia is the most aggressive causing cells to multiply very rapidly in the blood and blood marrow. Although there are treatments for acute leukemia, survival rates depend on a variety of factors including a person’s age and how progressive their disease is.
To add to treatments available for acute leukemia, Syndax Pharmaceuticals, Inc. recently announced Phase 1 results for its Phase 1/2 AUGMENT-101 trial of revumenib in people with nucleophosmin mutant (
Of the 60 people included in the study, 18 of them experienced complete remission or complete remission with partial recovery of peripheral blood counts (CR/CRh) for a little over nine months after treatment.
The results were also published in a study in the journal
Nucleophosmin mutant (mNPM1) acute leukemia is a type of acute myeloid leukemia (AML) — a cancer of the blood cells. Although AML can happen at any age, it is most common in people
The mNPM1 acute leukemia occurs when the nucleophosmin (NPM1) gene in the body becomes mutated. About 30% of all cases of AML are caused by an NPM1 gene mutation.
KMT2A-rearranged (KMT2Ar) relapsed/refractory (R/R) acute leukemia occurs from a mutation of the
Read the full article here